The latest in Epic’s fight over patient health datanews2026-03-17T16:22:55+00:00March 17th, 2026|Endpoints News|
Pfizer’s next-gen breast cancer data; Bristol Myers’ PRMT5 candidatenews2026-03-17T14:24:48+00:00March 17th, 2026|Endpoints News|
Rhythm’s Imcivree fails Phase 3 rare form obesity trialnews2026-03-17T13:48:31+00:00March 17th, 2026|Endpoints News|
Bicycle to cut 30% of staff after cancer drug’s regulatory setbacknews2026-03-17T13:32:34+00:00March 17th, 2026|Endpoints News|
Roche, Nvidia to build largest ‘AI factory’ in pharmanews2026-03-17T11:30:11+00:00March 17th, 2026|Endpoints News|
New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2bnews2026-03-17T11:00:34+00:00March 17th, 2026|Endpoints News|
J&J pulls out of NYC biotech incubator as it shrinks locationsnews2026-03-17T11:00:29+00:00March 17th, 2026|Endpoints News|
China mRNA therapy startup Innorna to test gout treatment in USnews2026-03-17T11:00:08+00:00March 17th, 2026|Endpoints News|
Federal judge halts CDC’s childhood vaccine overhaul news2026-03-16T20:37:18+00:00March 16th, 2026|Endpoints News|
BioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concernnews2026-03-16T18:55:04+00:00March 16th, 2026|Endpoints News|
